Jeffrey T. Ha

Jeffrey T. Ha

Auto-generated profile, based on publicly available information

Jeffrey T. Ha

The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2023 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
JHJeffrey T. Ha
Jeffrey T. Ha
SFS. Ben Freedman
S. Ben Freedman
DKDearbhla M. Kelly
Dearbhla M. Kelly
BNBrendon L. Neuen
Brendon L. Neuen
VPVlado Perkovic
Vlado Perkovic
SBSunil V. Badve
Sunil V. Badve

17 May 2023 in Kidney Medicine
Verified
Journal Article
Open access
JHJeffrey T. Ha
Jeffrey T. Ha
ASAnish Scaria
Anish Scaria
JAJason Andrade
Jason Andrade
SBSunil V. Badve
Sunil V. Badve
PBPeter Birks
Peter Birks
MJMin Jun
Min Jun
The benefit–risk profile of rivaroxaban versus warfarin for atrial fibrillation (AF) in patients with chronic kidney disease is uncertain. We compared rivaroxaban with warfarin across the range of kidney function in adults with AF. Multicenter retrospective cohort. Adults with AF and a measure of estimated glomerular filtration rate (eGFR); using administrative data from 5 jurisdictions across Australia and Canada (2011-2018). Kidney function was categorized as eGFR ≥60, 45-59, 30-44, and <30 mL/min/1.73 m2. Patients receiving dialysis and kidney transplant recipients were excluded. New dispensation of either rivaroxaban or warfarin. Composite (1) effectiveness outcome (all-cause death, ischemic stroke, or transient ischemic attack) and (2) major bleeding events (intracranial, gastrointestinal, or other) at 1 year. Cox proportional hazards models accounting for propensity score matching were performed independently in each jurisdiction and then pooled using random-effects meta-analysis. 55,568 patients (27,784 rivaroxaban–warfarin user matched pairs; mean age 74 years, 46% female, 33.5% with eGFR <60 mL/min/1.73 m2) experienced a total of 4,733 (8.5%) effectiveness and 1,144 (2.0%) bleeding events. Compared to warfarin, rivaroxaban was associated with greater or similar effectiveness across a broad range of kidney function (pooled HRs of 0.72 [95% CI, 0.66-0.78], 0.78 [95% CI, 0.58-1.06], 0.70 [95% CI, 0.57-0.87], and 0.78 [95% CI, 0.62-0.99]) for eGFR ≥60, 45-59, 30-44, and <30 mL/min/1.73 m2, respectively). Rivaroxaban was also associated with similar risk of major bleeding across all eGFR categories (pooled HRs of 0.75 [95% CI, 0.56-1.00], 1.01 [95% CI, 0.79-1.30], 0.87 [95% CI, 0.66-1.15], and 0.63 [95% CI, 0.37-1.09], respectively). Unmeasured treatment selection bias and residual confounding. In adults with AF, rivaroxaban compared with warfarin was associated with lower or similar risk of all-cause death, ischemic stroke and transient ischemic attack and similar risk of bleeding across a broad range of kidney function. This real-world study involved a large cohort of 55,568 adults with atrial fibrillation from 5 jurisdictions across Australia and Canada. It showed that the favorable safety (bleeding) and effectiveness (stroke or death) profile of rivaroxaban compared with warfarin was consistent across different levels of kidney function. This study adds important safety data on the use of rivaroxaban in patients with reduced kidney function, including those with estimated glomerular filtration rate <30 mL/min/1.73 m2 in whom the risks and benefits of rivaroxaban use is most uncertain. Overall, the study supports the use of rivaroxaban as a safe and effective alternative to warfarin for atrial fibrillation across differing levels of kidney function.

23 May 2018 in Australian Journal of Primary Health
Verified
Journal Article
Closed access
PDF file
JTJay Thakkar
Jay Thakkar
JRJulie Redfern
Julie Redfern
EKEhsan Khan
Ehsan Khan
EAEmily Atkins
Emily Atkins
JHJeffrey Ha
Jeffrey Ha
CCClara Chow
Clara Chow
The ‘Tobacco, Exercise and Diet Messages’ (TEXT ME) study was a 6-month, single-centre randomised clinical trial (RCT) that found a text message support program improved levels of cardiovascular risk factors in patients with coronary heart disease (CHD). The current analyses examined whether receipt of text messages influenced participants’ engagement with conventional healthcare resources. The TEXT ME study database (N = 710) was linked with routinely collected health department databases. Number of doctor consultations, investigations and cardiac medication prescriptions in the two study groups were compared. The most frequently accessed health service was consultations with a General Practitioner (mean 7.1, s.d. 5.4). The numbers of medical consultations, biochemical tests or cardiac-specific investigations were similar between the study groups. There was at least one prescription registered for statin, ACEI/ARBs and ß-blockers in 79, 66 and 50% of patients respectively, with similar refill rates in both the study groups. The study identified TEXT ME text messaging program did not increase use of Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) captured healthcare services. The observed benefits of TEXT ME reflect direct effects of intervention independent of conventional healthcare resource engagement.

9 April 2025 in Kidney360
Verified
Journal Article
Open access
DLDickson Lam
Dickson Lam
ASAnish Scaria
Anish Scaria
JAJason G Andrade
Jason G Andrade
SBSunil V. Badve
Sunil V. Badve
PBPeter Birks
Peter Birks
JHJeffrey T. Ha
Jeffrey T. Ha
Key Points: This real-world study involved a large cohort of 38,598 adults with atrial fibrillation from five jurisdictions across Australia and Canada. This study supports the use of apixaban as a safe and effective alternative to warfarin for atrial fibrillation across differing levels of kidney function. This study also adds important safety data on the use of apixaban in patients with reduced kidney function. Background: Evidence to guide the use of apixaban in people with atrial fibrillation (AF) and CKD in routine clinical practice has been limited. We assessed comparative safety (major bleeding) and effectiveness (ischemic stroke and death) of apixaban versus warfarin in patients with AF across the spectrum of non–dialysis-dependent CKD using large, routinely collected data. Methods: We combined findings from five retrospective cohorts (2013–2018) across Australia and Canada. Adults with AF, new dispensation of apixaban or warfarin, and a recorded eGFR grouped as ≥60, 45–59, 30–44, and <30 ml/min per 1.73 m2 were included. Patients on dialysis or kidney transplant recipients were excluded. We assessed outcomes within 1 year of initiating either therapy: (1) composite of all-cause death, ischemic stroke, or transient ischemic attack and (2) first hospitalization for major bleeding (intracranial, gastrointestinal, or other). Cox models estimated hazard ratios (HRs; 95% confidence intervals) for outcomes across eGFR categories, after 1:1 matching using propensity scores. We summarized center-level data using random effects meta-analysis. Results: Among 38,598 matched apixaban and warfarin users, there were 4130 (10.7%) ischemic and 697 (1.8%) bleeding events within 1 year. Apixaban was associated with lower or similar risk for the ischemic outcome compared with warfarin in all eGFR categories (pooled HRs [95% confidence interval]: 0.78 [0.64 to 0.94], 0.77 [0.62 to 0.97], 0.82 [0.68 to 0.98], and 0.99 [0.68 to 1.45] for eGFR ≥60, 45–59, 30–44, and <30 ml/min per 1.73 m2, respectively). Apixaban was associated with lower or similar risk of bleeding across the range of kidney function (pooled HRs: 0.55 [0.43 to 0.69], 0.73 [0.52 to 1.02], 0.55 [0.31 to 0.97], and 0.68 [0.47 to 0.99], respectively). There was no significant heterogeneity across jurisdictions or eGFR categories. Conclusions: In adults with AF and non–dialysis-dependent CKD, apixaban compared with warfarin was associated with lower or similar risk of ischemic and bleeding outcomes. Our results suggest that apixaban offers a favorable risk-benefit ratio in patients with AF independent of kidney function.

3 July 2025 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
JHJeffrey T. Ha
Jeffrey T. Ha
RFRobert A. Fletcher
Robert A. Fletcher
CAClare Arnott
Clare Arnott
MJMin Jun
Min Jun
SKSradha S. Kotwal
Sradha S. Kotwal
BNBrendon L. Neuen
Brendon L. Neuen

19 June 2026 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
RDRui Du
Rui Du
HWHannah Wallace
Hannah Wallace
JHJeffrey T Ha
Jeffrey T Ha
BTBen Talbot
Ben Talbot
VPVlado Perkovic
Vlado Perkovic
SKSradha Kotwal
Sradha Kotwal
Background and hypothesis: Chronic kidney disease (CKD) is a growing global health burden. While studies have demonstrated sex disparities in CKD prevalence and outcomes, evidence on sex-based differences in therapeutic management remains limited. This analysis aims to assess sex disparities in the receipt of evidence-based medications in a global CKD cohort. Methods: This study is a substudy of the Global Kidney Patient Trials Network, a prospective, observational, international cohort of CKD patients. The exposure of this study is biological sex, and the main outcomes are the receipt of evidence-based medications for CKD, including renin–angiotensin system inhibitors (RASis), sodium–glucose co-transporter 2 inhibitor (SGLT2i), and diuretics. Adjusted multivariable logistic models were conducted to examine associations between sex and proportion of receiving medications, as well as the interactions between sex and other key clinical characteristics (advanced age, high Kidney Disease: Improving Global Outcomes prognosis risk, and comorbid condition). Results: A total of 4192 participants were eligible, and 40.9% were female. Females had lower odds of receiving RASi [odds ratio (OR) = 0.75, 95% confidence interval (CI) 0.64–0.88; P < .001] and SGLT2i (OR = 0.79, 95% CI 0.64–0.98; P = .03) compared to males, after adjusting for age, region, systolic blood pressure, body mass index, presence of cardiovascular disease and diabetes, CKD aetiology, and prognosis risk, with no significant difference in the receipt of diuretics. There were no significant interactions between sex and any other key clinical characteristics, indicating that the disparities in the receipt of RASi and SGLT2i remained consistent across high-risk subgroups. Conclusion: Female patients with CKD are less likely to receive evidence-based medications than males, irrespective of established CKD risk factors. This difference highlights potential inequities in treatment globally that may result in outcome disparities.